2018Journal of Medical CasesOpen access

Sugammadex for Rapid Intraoperative Reversal of Neuromuscular Blockade in a Neonate

Mayuko Wakimoto, Candice Burrier, Joseph D. Tobias

Open full text 2 citations

Abstract

Sugammadex is a novel pharmacologic agent for the reversal of neuromuscular blockade, which selectively encapsulates the neuromuscular blocking agent (NMBA) thereby effectively removing it from the plasma concentration. In contrast to acetylcholinesterase inhibitors, sugammadex is able to reverse even profound neuromuscular blockade occurring immediately after the administration of a NMBA. Given this clinical effect, it has been suggested for use in critical clinical situations where rapid reversal of neuromuscular blockade is required. We report the use of sugammadex to reverse neuromuscular blockade following difficulty with positive pressure ventilation after endotracheal intubation in a neonate with a tracheoesophageal fistula. The potential for its use in critical airway and ventilation scenarios is reviewed. J Med Cases. 2018;9(12):400-402 doi: https://doi.org/10.14740/jmc3213

Open-access reader

About this research paper

What this paper is about

Sugammadex is a novel pharmacologic agent for the reversal of neuromuscular blockade, which selectively encapsulates the neuromuscular blocking agent (NMBA) thereby effectively removing it from the plasma concentration. In contrast to acetylcholinesterase inhibitors, sugammadex is able to reverse even profound neuromuscular blockade occurring immediately after the administration of a NMBA. Given this clinical effect, it has been suggested for use in critical clinical situations where rapid reversal of neuromuscular blockade is required. We report the use of sugammadex to reverse neuromuscular blockade following difficulty with positive pressure ventilation after endotracheal intubation in a neonate with a tracheoesophageal fistula. The potential for its use in critical airway and ventilation scenarios is reviewed. J Med Cases. 2018;9(12):400-402 doi: https://doi.org/10.14740/jmc3213

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Sugammadex is a novel pharmacologic agent for the reversal of neuromuscular blockade, which selectively encapsulates the neuromuscular blocking agent (NMBA) thereby effectively removing it from the plasma concentration. In contrast to acetylcholinesterase inhibitors, sugammadex is able to reverse even profound neuromuscular blockade occurring immediately after the administration of a NMBA. Given this clinical effect, it has been suggested for use in critical clinical situations where rapid reversal of neuromuscular blockade is required. We report the use of sugammadex to reverse neuromuscular blockade following difficulty with positive pressure ventilation after endotracheal intubation in a neonate with a tracheoesophageal fistula. The potential for its use in critical airway and ventilation scenarios is reviewed. J Med Cases. 2018;9(12):400-402 doi: https://doi.org/10.14740/jmc3213

Key concepts: Sugammadex, Neuromuscular Blockade, Medicine, Anesthesia, Blockade, Neuromuscular Blocking Agents, Rocuronium, Neuromuscular monitoring

Related papers

Back to paper searchBrowse research topicsOriginal source
Sugammadex for Rapid Intraoperative Reversal of Neuromuscular Blockade in a Neonate — Research Paper | ScholarLens